This compound is supplied for in-vitro and preclinical research only. It is not a medicinal product. It is not approved for human or veterinary use in any jurisdiction. No therapeutic, medicinal, cosmetic, or performance-enhancement claims are made or implied. By proceeding to inquire, you confirm you are an adult researcher acquiring this compound within your own research framework. Full terms on the Research Use Only page.
5-Amino-1MQ
50 mg freeze-dried vial, NNMT inhibitor
Compound specifications, chemistry, and storage.
Technical specifications
Specimen format| Compound name | 5-Amino-1MQ |
| Also known as | 5-amino-1-methylquinolinium, NNMTi |
| CAS number | 1421927-72-3 |
| PubChem CID | 129317894 → |
| InChI Key | XBFAQDYHFAPWSV-UHFFFAOYSA-N |
| SMILES | Reference SMILES on COA |
| Empirical formula (Hill notation) | C10H12N2 |
| Molecular weight | 160.22 g/mol (monoisotopic mass: 160.10) |
| Salt form | Iodide salt (typical research grade) |
| Counter-ion content | Quantified per batch on COA. Custom salt forms (chloride, ammonium, TFA) available on quote. |
| Sequence (1-letter) | Not applicable (small molecule) |
| Sequence (3-letter) | Not applicable; 5-amino-1-methylquinolinium small molecule |
| Length | Small molecule, not a peptide |
| Weight basis | Gross weight per industry standard. Net peptide content quantified on batch COA. |
| Quantity per vial | 50 mg |
| Format | Freeze-dried white powder or thin film, sealed under inert atmosphere. Why does the vial look empty? |
| Appearance | White freeze-dried cake or powder. May also appear as a thin film on the vial wall. |
| Solubility | Water soluble, reconstituted with bacteriostatic water (1 to 2 ml typical) |
| Solution colour | Clear and colourless when correctly reconstituted |
| Purity (HPLC) | Specification ≥98.5%, tested before listing |
| Identity confirmation | LC-MS, batch-specific spectrum on COA |
| Endotoxin (LAL) | Within Ph. Eur. specification, batch report on COA |
| Storage (freeze-dried) | 2 to 8 degrees Celsius, sealed, protected from light. Avoid thermal cycling. |
| Storage (reconstituted) | 2 to 8 degrees Celsius. Use within 4 to 6 weeks. Avoid repeated freeze-thaw. |
| Shelf life | 24 months from synthesis date when storage conditions are maintained |
| Country of synthesis | EU partner facility, Ph. Eur. methodology references |
| Application | In-vitro and preclinical research only. Not for human or veterinary use. |
Mitochondrial & metabolic research
Primary research area. Studied for NNMT-pathway involvement in NAD+ regulation and adipose tissue biology.
Open research area → 02Methylation balance & metabolic signalling
Secondary research area. Studied for downstream effects on cellular methylation and inflammatory pathways.
Open research area →A small-molecule NNMT inhibitor, and what the published research investigates.
5-Amino-1MQ is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in adipose tissue metabolism, NAD+ regulation, and cellular methylation balance. Unlike the peptides elsewhere in the Cresten catalogue, 5-Amino-1MQ is a non-peptide small molecule, included here because the published research base sits at the intersection of metabolic and longevity peptide research and because researchers comparing NNMT inhibitor work with adjacent peptide protocols often source from the same supplier. The sections below summarise what the published preclinical literature investigates, what Cresten supplies, and what the certificate of analysis confirms.
Where 5-Amino-1MQ comes from.
5-Amino-1MQ (5-amino-1-methylquinolinium) is not a peptide. It is a small synthetic molecule, a methylquinolinium derivative, and it sits in this catalogue because it is studied alongside peptides in the same metabolic and longevity research conversation, not because it shares their chemistry. It is worth being clear about that up front: where the peptides here are built residue by residue, 5-Amino-1MQ is a defined small-molecule compound, supplied freeze-dried, molecular weight near 159 g/mol for the cation.
It came out of research into enzyme inhibitors rather than out of peptide synthesis. The compound is prepared by standard small-molecule synthesis and purified to a defined specification; identity is confirmed by mass and the certificate reports purity for the small molecule, which is a different analytical profile from a lyophilized peptide cake.
What the research looks at.
5-Amino-1MQ is studied as an inhibitor of nicotinamide N-methyltransferase, usually shortened to NNMT. NNMT is an enzyme that methylates nicotinamide, and it sits at a junction of two things metabolic researchers care about: the cell's supply of NAD precursors, and the methylation economy of the cell. The research thesis is that inhibiting NNMT could shift that balance, and the published work, largely in cell and animal models, has looked at NNMT inhibition in the context of adipose tissue, metabolic rate, and muscle.
The most cited line of research is in obesity and metabolic models in mice, where NNMT inhibition has been examined in relation to adipocyte energy handling. There is also interest in NNMT in muscle and in some cancer biology, because the enzyme is expressed differently across those tissues. The body of work is younger and smaller than for the well-studied peptides; the PubMed record is real but the compound has nothing approaching a clinical trial record.
"NNMT inhibition is the mechanism the literature is built on; the downstream metabolic effects are still being worked out in preclinical models."
Where the published research does not go: there are no human trials establishing a use, and the animal metabolic results do not translate to a human outcome. The compound is supplied as a research compound. What it is studied for is in the literature, and we link what is indexed. We do not narrate an outcome for you.
What the certificate confirms.
Every Cresten batch of 5-Amino-1MQ ships with a certificate from an analytical lab, against the test panel described on the Methodology page. The certificate that ships with your batch confirms:
The certificate format is shown on the batch verification page.
Selected published research on 5-Amino-1MQ.
Monograph last reviewed 26 May 2026 · references checked against PubMed
The curated reference list for 5-Amino-1MQ is being finalised against PubMed and will appear here. In the meantime, the indexed literature is available directly: PubMed results for 5-Amino-1MQ.
What this monograph is not
This monograph summarises what the published research looks at regarding 5-Amino-1MQ mechanism. It is not a therapeutic recommendation. It is not dosing guidance. It is not a clinical protocol. It is not medical advice.
Cresten Labs supplies 5-Amino-1MQ as a research compound for lab-based research only. The decision to investigate any compound in any research framework is the researcher’s decision, within their own ethical, legal, and methodological boundaries.
Cresten makes no claim about human therapeutic use, no claim about clinical effectiveness, no claim about safety in human use, and no claim that this compound has been reviewed by any regulator for any medical use.
Frequently asked questions about 5-Amino-1MQ
Common research-protocol and supply questions about 5-Amino-1MQ, with answers grounded in published peer-reviewed research and Cresten Labs supply practice. All information is for in vitro and preclinical research only.
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule NNMT inhibitor, a 0-amino-acid peptide (CAS 54151-67-2, molecular weight 159.19 g/mol). Cresten Labs supplies 5-Amino-1MQ as a freeze-dried vial for in vitro and preclinical research only, with each batch verified at Janoshik Analytical.
What does research suggest 5-Amino-1MQ does?
Published research investigates 5-Amino-1MQ for selective inhibition of nicotinamide N-methyltransferase (NNMT), modulating cellular methylation balance and metabolic-pathway markers in research. The compound is studied primarily in NNMT inhibition and metabolic pathway research. 5-Amino-1MQ is supplied for research use only and is not approved by any regulator for medical use.
What is the typical 5-Amino-1MQ dosage in published research?
Published 5-Amino-1MQ dosage in research protocols ranges from 10 to 200 mg per administration in research protocols (oral), taken orally, with daily oral dosing in metabolic and longevity research. Cresten Labs publishes the typical 5-Amino-1MQ protocol ranges as research-protocol references only; this is not dosing guidance for human use.
How is 5-Amino-1MQ prepared for research use?
oral preparation; reconstitution typically not applicable. 5-Amino-1MQ is a small-molecule oral preparation, not a lyophilized peptide; injection reconstitution does not apply. Use within the shelf-life window noted on the COA. Storage and handling per published research protocols.
What is the 5-Amino-1MQ half-life and how is 5-Amino-1MQ storage handled?
Published research reports 5-Amino-1MQ systemic half-life at short half-life; daily dosing typical. 5-Amino-1MQ storage: powder stored at room temperature, away from moisture and light. The Cresten certificate of analysis lists the synthesis date, batch identifier, and the storage conditions verified for this specific batch.
5-Amino-1MQ vs MOTS-c: how do they compare in research?
In published research comparing 5-Amino-1MQ vs MOTS-c, 5-Amino-1MQ inhibits NNMT while MOTS-c modulates mitochondrial signaling; the two are sometimes combined in metabolic-stress and longevity research. The two compounds are studied separately and in combination depending on the research question. Cresten Labs supplies both as verified research compounds.
What does research literature report about 5-Amino-1MQ side effects?
Published 5-Amino-1MQ research reports the following: preclinical research reports tolerability across tested dose ranges; long-term human data remains limited. Cresten Labs supplies the compound for research use only; clinical-use side-effect data should be drawn from peer-reviewed clinical trial publications, not from research-vendor pages.
Where to buy 5-Amino-1MQ in Europe?
Cresten Labs supplies 5-Amino-1MQ across the EU single market to 16 European countries. Each 5-Amino-1MQ batch is tested at Janoshik Analytical with the certificate of analysis published on the website before it lists. 5-Amino-1MQ is sold for in vitro and preclinical research only, not for human or veterinary use.
How is 5-Amino-1MQ verified at Cresten Labs?
Every 5-Amino-1MQ batch is tested at Janoshik Analytical in Czech Republic, an third-party peptide-analysis laboratory. Each batch certificate documents HPLC purity, mass-spectrometry identity confirmation, and contamination panels. The certificate publishes with the batch, before it lists.
What is the typical 5-Amino-1MQ stack in published research?
In published research, the typical 5-Amino-1MQ stack pairs the compound with MOTS-c. 5-Amino-1MQ inhibits NNMT while MOTS-c modulates mitochondrial signaling; the two are sometimes combined in metabolic-stress and longevity research.